Literature DB >> 19923925

Impairment of mitochondrial respiration in mouse fibroblasts by oncogenic H-RAS(Q61L).

Dianer Yang1, Man-Tzu Wang, Yong Tang, Yakun Chen, Hongmei Jiang, Torrie T Jones, Krishna Rao, Gregory J Brewer, Keshav K Singh, Daotai Nie.   

Abstract

A common metabolic change in cancer is the acquisition of glycolytic phenotypes. Increased expression of glycolytic enzymes is considered as one contributing factor. The role of mitochondrial defects in acquisition of glycolytic phenotypes has been postulated but remains controversial. Here we show that functional defects in mitochondrial respiration could be induced by oncogenic H-Ras(Q61L) transformation, even though the mitochondrial contents or mass was not reduced in the transformed cells. First, mitochondrial respiration, as measured by mitochondrial oxygen consumption, was suppressed in NIH-3T3 cells transformed with H-Ras(Q61L). Second, oligomycin or rotenone did not reduce the cellular ATP levels in the H-Ras(Q61L) transformed cells, suggesting a diminished role of mitochondrial respiration in the cellular energy metabolism. Third, inhibition of glycolysis with iodoacetic acid reduced ATP levels at a much faster rate in H-Ras(Q61L) transformed cells than in the vector control cells. The reduction of cellular ATP levels was reversed by exogenously added pyruvate in the vector control cells but not in H-Ras(Q61L) transformed cells. Finally when compared to the HRas(Q61L) transformed cells, the vector control cells had increased resistance toward glucose deprivation. The increased resistance was dependent on mitochondrial oxidative phosphorylation since rotenone or oligomycin abolished the increased survival of the vector control cells under glucose deprivation. The results also suggest an inability of the H-Ras(Q61L) transformed cells to reactivate mitochondrial respiration under glucose deprivation. Taken together, the data suggest that mitochondrial respiration can be impaired during transformation of NIH-3T3 cells by oncogeneic H-Ras(Q61L).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19923925      PMCID: PMC2909490          DOI: 10.4161/cbt.9.2.10379

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  22 in total

Review 1.  RAS oncogenes: the first 30 years.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

2.  High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers.

Authors:  S Walenta; M Wetterling; M Lehrke; G Schwickert; K Sundfør; E K Rofstad; W Mueller-Klieser
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

3.  Effect of oncogene transformation of rat embryo cells on cellular oxygen consumption and glycolysis.

Authors:  J E Biaglow; G Cerniglia; S Tuttle; V Bakanauskas; C Stevens; G McKenna
Journal:  Biochem Biophys Res Commun       Date:  1997-06-27       Impact factor: 3.575

4.  Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins.

Authors:  L A Feig; G M Cooper
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

5.  Biological and biochemical properties of human rasH genes mutated at codon 61.

Authors:  C J Der; T Finkel; G M Cooper
Journal:  Cell       Date:  1986-01-17       Impact factor: 41.582

6.  Glucose-induced stimulation of the Ras-cAMP pathway in yeast leads to multiple phosphorylations and activation of 6-phosphofructo-2-kinase.

Authors:  Hassan Dihazi; Renate Kessler; Klaus Eschrich
Journal:  Biochemistry       Date:  2003-05-27       Impact factor: 3.162

7.  Correlation of high lactate levels in human cervical cancer with incidence of metastasis.

Authors:  G Schwickert; S Walenta; K Sundfør; E K Rofstad; W Mueller-Klieser
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

8.  Mitochondrial STAT3 supports Ras-dependent oncogenic transformation.

Authors:  Daniel J Gough; Alicia Corlett; Karni Schlessinger; Joanna Wegrzyn; Andrew C Larner; David E Levy
Journal:  Science       Date:  2009-06-26       Impact factor: 47.728

Review 9.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

10.  BRAF and RAS mutations in human lung cancer and melanoma.

Authors:  Marcia S Brose; Patricia Volpe; Michael Feldman; Madhu Kumar; Irum Rishi; Renee Gerrero; Eugene Einhorn; Meenhard Herlyn; John Minna; Andrew Nicholson; Jack A Roth; Steven M Albelda; Helen Davies; Charles Cox; Graham Brignell; Philip Stephens; P Andrew Futreal; Richard Wooster; Michael R Stratton; Barbara L Weber
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

View more
  25 in total

1.  Kinase suppressor of ras 1 (KSR1) regulates PGC1α and estrogen-related receptor α to promote oncogenic Ras-dependent anchorage-independent growth.

Authors:  Kurt W Fisher; Binita Das; Robert L Kortum; Oleg V Chaika; Robert E Lewis
Journal:  Mol Cell Biol       Date:  2011-04-25       Impact factor: 4.272

2.  Transformation by different oncogenes relies on specific metabolic adaptations.

Authors:  Paolo Peruzzo; Marina Comelli; Eros Di Giorgio; Elisa Franforte; Irene Mavelli; Claudio Brancolini
Journal:  Cell Cycle       Date:  2016-08-02       Impact factor: 4.534

3.  Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?

Authors:  Thomas N Seyfried; Laura Shelton; Gabriel Arismendi-Morillo; Miriam Kalamian; Ahmed Elsakka; Joseph Maroon; Purna Mukherjee
Journal:  Neurochem Res       Date:  2019-04-25       Impact factor: 3.996

4.  Differential programming of p53-deficient embryonic cells during rotenone block.

Authors:  M L Green; A V Singh; L B Ruest; M M Pisano; R A Prough; T B Knudsen
Journal:  Toxicology       Date:  2011-08-27       Impact factor: 4.221

5.  Release of targeted p53 from the mitochondrion as an early signal during mitochondrial dysfunction.

Authors:  M L Green; M M Pisano; R A Prough; T B Knudsen
Journal:  Cell Signal       Date:  2013-07-27       Impact factor: 4.315

Review 6.  Mitochondria and Cancer.

Authors:  Wei-Xing Zong; Joshua D Rabinowitz; Eileen White
Journal:  Mol Cell       Date:  2016-03-03       Impact factor: 17.970

7.  Effects of Low Concentrations of Rotenone upon Mitohormesis in SH-SY5Y Cells.

Authors:  Xiong Yuyun; Qian Jinjun; Xu Minfang; Qiu Jing; Xia Juan; Ma Rui; Zhu Li; Gao Jing
Journal:  Dose Response       Date:  2012-07-10       Impact factor: 2.658

Review 8.  Impaired mitochondrial metabolism and mammary carcinogenesis.

Authors:  Nagendra Yadava; Sallie S Schneider; D Joseph Jerry; Chul Kim
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-12-27       Impact factor: 2.673

Review 9.  AMPK: a contextual oncogene or tumor suppressor?

Authors:  Jiyong Liang; Gordon B Mills
Journal:  Cancer Res       Date:  2013-05-03       Impact factor: 12.701

10.  Identification of NDUFAF1 in mediating K-Ras induced mitochondrial dysfunction by a proteomic screening approach.

Authors:  Peng Wang; Ming Song; Zhao-lei Zeng; Chao-feng Zhu; Wen-hua Lu; Jing Yang; Ming-zhe Ma; A-min Huang; Yumin Hu; Peng Huang
Journal:  Oncotarget       Date:  2015-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.